Erratum to: Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen?-Reference-Cited by-同舟云学术

Erratum to: Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen?

Published:2024-03-11 Issue:1 Volume:38 Page:10-10
ISSN:1011-6583
Container-title:Review of Clinical Pharmacology and Pharmacokinetics - International Edition
language:
Short-container-title:Rev. Clin. Pharmacol. Pharmacokinet., Int. Ed.

Author:

Iatrakis Georgios^ORCID, ,Zervoudis Stefanos^ORCID,Sarella Angeliki^ORCID,Tsikouras Panagiotis^ORCID,Paschopoulos Minas^ORCID,Balafouta Myrsini^ORCID,Peitsidis Panagiotis^ORCID, , , , , , ,

Abstract

Due to an unfortunate oversight of the corresponding author, Anastasia Bothou was included as an author of the editorial without her consent and knowledge. The citation of the editorial has now been amended as follows: Iatrakis G., Zervoudis S., Sarella A., Tsikouras P., Paschopoulos M., Balafouta M., Peitsidis P. Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen? Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38(1): 7-9 (2024). https://doi.org/10.61873/OEFM7580. The publisher will update the PDF and HTML versions of the paper on the journal's website, and will alert downstream indexes and databases through supplying updated metadata.

Publisher

PHARMAKON-Press

Reference11 articles.

1. 1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M., Forbes J.F., Bradley R., Ingle J., Aihara T., Bliss J., Boccardo F., Coates A., Coombes R.C., Cuzick J., Dubsky P., Gnant M., Kaufmann M., Kilburn L., Perrone F., Rea D., Thürlimann B., van de Velde C., Pan H., Peto R., Davies C., Gray R. Aromatase inhibitors versus ta¬moxifen in early breast cancer: pa¬tient-level meta-analysis of the randomised trials. Lancet; 386: 1341-52 (2015).

2. 2. Goldstein S.R., Bakkum-Gamez J.N. Abnormal uter¬ine bleeding and uterine pathology in patients on ta¬mox¬ifen therapy. UpToDate 2023.

3. 3. Chalas E., Costantino J.P., Wickerham D.L., Wolmark N., Lewis G.C., Bergman C., Runowicz C.D. Benign gy-necologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol. 192: 1230-7 (2005).

4. 4. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in ta-moxifen-treated breast cancer patients: find¬ings from the National Surgical Adjuvant Breast and Bowel Pro¬ject (NSABP) B-14. J Natl Cancer Inst. 86: 527-37 (1994).

5. 5. Feldman S., M.D., Levine D. Overview of the evalu¬ation of the endometrium for malignant or premalig¬nant dis¬ease. UpToDate 2023.